GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (LTS:0LC7) » Definitions » Shiller PE Ratio

Syros Pharmaceuticals (LTS:0LC7) Shiller PE Ratio : (As of May. 05, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Syros Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Syros Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Syros Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals Shiller PE Ratio Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Syros Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Syros Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Shiller PE Ratio falls into.


;
;

Syros Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Syros Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Syros Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.16/133.0289*133.0289
=-0.160

Current CPI (Sep. 2024) = 133.0289.

Syros Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 0.000 99.070 0.000
201503 -3.223 99.621 -4.304
201506 -28.698 100.684 -37.917
201509 -38.020 100.392 -50.380
201512 -46.739 99.792 -62.306
201603 -5.415 100.470 -7.170
201606 -54.200 101.688 -70.905
201609 -6.500 101.861 -8.489
201612 -4.690 101.863 -6.125
201703 -4.900 102.862 -6.337
201706 -5.200 103.349 -6.693
201709 -5.300 104.136 -6.771
201712 -5.800 104.011 -7.418
201803 -4.800 105.290 -6.065
201806 -4.300 106.317 -5.380
201809 -4.700 106.507 -5.870
201812 -5.400 105.998 -6.777
201903 -4.900 107.251 -6.078
201906 -4.700 108.070 -5.785
201909 -4.700 108.329 -5.772
201912 -4.600 108.420 -5.644
202003 -3.900 108.902 -4.764
202006 -3.800 108.767 -4.648
202009 -4.300 109.815 -5.209
202012 -6.300 109.897 -7.626
202103 -2.300 111.754 -2.738
202106 -3.600 114.631 -4.178
202109 -4.140 115.734 -4.759
202112 -3.780 117.630 -4.275
202203 -3.990 121.301 -4.376
202206 -5.400 125.017 -5.746
202209 -3.210 125.227 -3.410
202212 -0.236 125.222 -0.251
202303 -0.850 127.348 -0.888
202306 -1.300 128.729 -1.343
202309 -1.430 129.860 -1.465
202312 -2.220 129.419 -2.282
202403 -0.100 131.776 -0.101
202406 -0.590 132.554 -0.592
202409 -0.160 133.029 -0.160

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Syros Pharmaceuticals  (LTS:0LC7) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Syros Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Syros Pharmaceuticals Business Description

Traded in Other Exchanges
Address
35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Syros Pharmaceuticals Headlines

No Headlines